Safety and Pharmacokinetics Study of Intranasal Ketorolac in Elderly and Nonelderly Adult Healthy Subjects
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
This study had an open-label, single-dose design. All subjects received a single dose of 30
mg of intranasal ketorolac. Blood samples for determination of ketorolac plasma levels were
obtained pre-dose and at specified time points over 24 hours post-dose.
The primary objective of this trial was to compare the pharmacokinetics of intranasal
ketorolac between elderly and nonelderly adult subjects. The secondary objective was to
evaluate the safety profile of intranasal ketorolac in elderly subjects.